Targeting RSV with Vaccines and Small Molecule Drugs
Overview
Affiliations
Respiratory syncytial virus (RSV) is the most significant cause of pediatric respiratory infections. Palivizumab (Synagis®), a humanized monoclonal antibody, has been used successfully for a number of years to prevent severe RSV disease in at-risk infants. However, despite intense efforts, there is no approved vaccine or small molecule drug for RSV. As an enveloped virus, RSV must fuse its envelope with the host cell membrane, which is accomplished through the actions of the fusion (F) glycoprotein, with attachment help from the G glycoprotein. Because of their integral role in initiation of infection and their accessibility outside the lipid bilayer, these proteins have been popular targets in the discovery and development of antiviral compounds and vaccines against RSV. This review examines advances in the development of antiviral compounds and vaccine candidates.
Mitra D, Paul M, Thatoi H, Mohapatra P In Silico Pharmacol. 2023; 12(1):5.
PMID: 38148755 PMC: 10749291. DOI: 10.1007/s40203-023-00178-w.
Synthesis and evaluation of 3-alkynyl-5-aryl-7-aza-indoles as broad-spectrum antiviral agents.
Martinez-Gualda B, Graus M, Camps A, Vanhulle E, Saul S, Azari S Front Chem. 2022; 10:1058229.
PMID: 36385995 PMC: 9643853. DOI: 10.3389/fchem.2022.1058229.
Respiratory syncytial virus entry and how to block it.
Battles M, McLellan J Nat Rev Microbiol. 2019; 17(4):233-245.
PMID: 30723301 PMC: 7096974. DOI: 10.1038/s41579-019-0149-x.
T Lymphocytes as Measurable Targets of Protection and Vaccination Against Viral Disorders.
Monette A, Mouland A Int Rev Cell Mol Biol. 2019; 342:175-263.
PMID: 30635091 PMC: 7104940. DOI: 10.1016/bs.ircmb.2018.07.006.
Hicks S, Chaiwatpongsakorn S, Costello H, McLellan J, Ray W, Peeples M J Virol. 2018; 92(15).
PMID: 29743373 PMC: 6052300. DOI: 10.1128/JVI.00621-18.